27 w Volunteer | No cancer,

Metronomic dosing
Metronomic dosing is a new concept of cancer chemotherapy in which anticancer lower dose drugs is administered than the maximum tolerated dose over a long period of time to treat cancers with fewer side effects. Metronomic chemotherapy is a productive model for this intellect, integrating the concepts of angiogenesis, tumoral microenvironment, stem cells, angiogenic cancer machinery, and tumoral immunology. The collaboration of molecular biological studies for preclinical and clinical investigations together, an appreciable prospect for metronomic chemotherapy.

The tumour transforms its surroundings to create a viable microenvironment and modifies the hosts' immune system, and establishes an appealing climate.
MTC (metronomic chemotherapy) enhances the cytotoxic response by inducing the antigen-presenting dendritic cell maturation, augmenting the function and increasing tumorigenic antigen presentation that foregathers the immunogenic cancer death, which can also be used as an antiproliferative effect on tumour cells or to sensitize the tumour to certain chemotherapy actions.

MTC in cancer
Cyclophosphamide (CP) and methotrexate (MTX) was on the top of the list to be tested in a metronomic scheme in breast cancer.
The combination was to modulate angiogenesis, drug resistance, apoptosis, and proliferation and subsequently prolonged the survival. There researches still ongoing about the current role of metronomic regimens in the treatment of cancer.
The cost of cancer treatment is another matter of concern. The expense of cancer treatment is increasing with more expensive drugs and increasing incidence.